- Home
- ZEO vs CMMB Comparison
ZEO vs CMMB Comparison
Compare ZEO & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZEO
- CMMB
- Stock Information
- Founded
- ZEO 2005
- CMMB 2004
- Country
- ZEO United States
- CMMB Israel
- Employees
- ZEO N/A
- CMMB N/A
- Industry
- ZEO
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- ZEO
- CMMB Health Care
- Exchange
- ZEO NYSE
- CMMB Nasdaq
- Market Cap
- ZEO 14.6M
- CMMB 15.8M
- IPO Year
- ZEO N/A
- CMMB N/A
- Fundamental
- Price
- ZEO $1.77
- CMMB $1.51
- Analyst Decision
- ZEO
- CMMB Strong Buy
- Analyst Count
- ZEO 0
- CMMB 3
- Target Price
- ZEO N/A
- CMMB $5.67
- AVG Volume (30 Days)
- ZEO 3.1M
- CMMB 206.1K
- Earning Date
- ZEO 11-20-2024
- CMMB 11-07-2024
- Dividend Yield
- ZEO N/A
- CMMB N/A
- EPS Growth
- ZEO N/A
- CMMB N/A
- EPS
- ZEO 0.67
- CMMB N/A
- Revenue
- ZEO $95,455,763.00
- CMMB N/A
- Revenue This Year
- ZEO N/A
- CMMB N/A
- Revenue Next Year
- ZEO N/A
- CMMB N/A
- P/E Ratio
- ZEO $2.66
- CMMB N/A
- Revenue Growth
- ZEO N/A
- CMMB N/A
- 52 Week Low
- ZEO $1.14
- CMMB $0.42
- 52 Week High
- ZEO $12.34
- CMMB $2.55
- Technical
- Relative Strength Index (RSI)
- ZEO 43.47
- CMMB 43.28
- Support Level
- ZEO $1.62
- CMMB $1.29
- Resistance Level
- ZEO $2.08
- CMMB $1.58
- Average True Range (ATR)
- ZEO 0.49
- CMMB 0.15
- MACD
- ZEO -0.01
- CMMB -0.04
- Stochastic Oscillator
- ZEO 22.03
- CMMB 39.29
About ZEO ZEO ENERGY CORP
Zeo Energy Corp is a vertically integrated provider of residential solar energy systems, other energy efficient equipment and related services currently serving customers in Florida, Texas, Arkansas, and Missouri. Its primary business activity is selling and installing residential solar energy systems that homeowners use to supplement the amount of usable electricity required to power their homes.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.